• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LEVETIRACETAM Drug Record

  • Summary
  • Interactions
  • Claims
  • LEVETIRACETAM chembl:CHEMBL1286 Approved

    Alternate Names:

    UCB-L059
    LEVETIRACETAM IN SODIUM CHLORIDE
    MATEVER
    LEVETIRACETAM
    DESITREND
    KEPPRA
    KEPPRA XR
    UCB-22059
    AGB-101
    SPRITAM
    N03AX14
    ELEPSIA XR

    Drug Info:

    Year of Approval 1999
    Drug Class anticonvulsants
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications anticonvulsant
    (2 More Sources)

    Publications:

    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Stahl, 2004, Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator., J Clin Psychiatry
    Newton et al., 2007, Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors., J. Neurooncol.
    De Smedt et al., 2007, Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data., CNS Drug Rev
    Lambeng et al., 2006, Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties., Neurosci. Lett.
    Gillard et al., 2006, Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein., Eur. J. Pharmacol.
    Lynch et al., 2004, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam., Proc. Natl. Acad. Sci. U.S.A.
    Johannessen Landmark, 2008, Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy., CNS Drugs
    Lukyanetz et al., 2002, Selective blockade of N-type calcium channels by levetiracetam., Epilepsia
    Yang TW et al., 2018, HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events., PLoS One
  • LEVETIRACETAM   SV2A

    Interaction Score: 22.08

    Interaction Types & Directionality:
    agonist (activating)
    modulator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Synaptic vesicle glycoprotein 2A modulator
    Trial Name levetiracetam ,Keppra, Keppra XR

    PMIDs:
    15367040 17431542 17461889 16434140 16556440 15210974 18072813


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • LEVETIRACETAM   CACNA1B

    Interaction Score: 1.26

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Voltage-gated N-type calcium channel alpha-1B subunit blocker
    Direct Interaction yes
    Trial Name levetiracetam ,Keppra, Keppra XR

    PMIDs:
    17461889 11879381


    Sources:
    TdgClinicalTrial ChemblInteractions

  • LEVETIRACETAM   HLA-A

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30020991


    Sources:
    PharmGKB

  • LEVETIRACETAM   SCN1A

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28753467 25155934 23859570 21747585


    Sources:
    PharmGKB

  • LEVETIRACETAM   CA1

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • LEVETIRACETAM   HTR3A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LEVETIRACETAM   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: LEVETIRACETAM

    • Version: 01-August-2011

    Alternate Names:
    LEVETIRACETAM Primary Drug Name

    Drug Info:
    Drug Class anticonvulsants
    Year of Approval 1999

    Publications:

  • TdgClinicalTrial: LEVETIRACETAM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticonvulsant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: levetiracetam

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure

  • TTD: Levetiracetam

    • Version: 2020.06.01

    Alternate Names:
    D0E1XL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1286

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1286

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21